Boehringer Ingelheim: Schizophrenia trials
The registry lists 11 Schizophrenia studies with Boehringer Ingelheim as lead sponsor. 0 are open to participants now and 10 have results posted.
Phase 1 2Phase 2 4Phase 3 4No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study to Test Long-term Safety of Iclepertin in People With Schizophrenia Who Took Part in a Previous CONNEX StudyTerminatedNCT05211947Phase 3Results posted
- CONNEX-3: A Study to Test Whether Iclepertin Improves Learning and Memory in People With SchizophreniaCompletedNCT04860830Phase 3Results posted
- Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-2)CompletedNCT04846881Phase 3Results posted
- Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-1)CompletedNCT04846868Phase 3Results posted
- This Study Tests Whether BI 425809 Together With Brain Training Using a Computer Improves Mental Functioning in Patients With SchizophreniaCompletedNCT03859973Phase 2Results posted
- This Study Tests Whether BI 409306 Prevents Patients With Schizophrenia From Becoming Worse. This Study Looks at How Well Patients Tolerate BI 409306 and How Effective it is Over 6 MonthsTerminatedNCT03351244Phase 2Results posted
- Clinical Trial of BI 425809 Effect on Cognition and Functional Capacity in SchizophreniaCompletedNCT02832037Phase 2Results posted
- Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Healthy VolunteersCompletedNCT02392468Phase 1Results posted
- A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.CompletedNCT02281773Phase 2Results posted
- Safety and Tolerability of BI 409306 in Patients With SchizophreniaCompletedNCT01892384Phase 1Results posted
- A Prospective Cohort Study to Assess Clinical Effectiveness of an Investigational Digital Therapeutic (CT-155) in Patients With Experiential Negative Symptoms of SchizophreniaCompletedNCT06791122Not applicable